BioBlast Pharma Raises $37M In NASDAQ IPO

August 3, 2014 | Israeli pharmaceutical company BioBlast announced that it raised $37 million in its NASDAQ IPO last week. The company priced 3,200,000 ordinary shares at $11 per share making gross proceeds of $35.2 million. The company also granted the underwriters 30 days to purchase up to 480,000 additional shares. BioBlasts offering, trading under the ticker ORPN is expected to close on August 5, 2014, subject to customary closings. BioBlast is an Israeli clinical stage biotechnology company founded in 2012 developing treatments for rare and ultra-rare genetic diseases.